Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Priya Nigam

RARE PHOTOS: Why nektar shares are down almost 35 | Vintage Vibes

Shares of Nektar Therapeutics (NASDAQ:NKTR) have come under pressure after the company “announced the discontinuation of the remaining clinical development programs of bempeg + nivo (Opdivo) in collaboration with Bristo,” according to BofA Securities.

The Nektar Therapeutics Analyst: Greg Harrison reiterated an Underperform rating for Nektar Therapeutics while reducing the price target from $6 to $5.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.